[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Profound Medical Corp (PROF)

Profound Medical Corp (PROF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 249,279
  • Shares Outstanding, K 36,338
  • Annual Sales, $ 16,100 K
  • Annual Income, $ -42,570 K
  • EBIT $ -41 M
  • EBITDA $ -41 M
  • 60-Month Beta 0.73
  • Price/Sales 15.12
  • Price/Cash Flow N/A
  • Price/Book 3.66

Options Overview Details

View History
  • Implied Volatility 117.19% (-12.95%)
  • Historical Volatility 70.29%
  • IV Percentile 50%
  • IV Rank 18.56%
  • IV High 445.45% on 02/18/26
  • IV Low 42.39% on 05/19/25
  • Expected Move (DTE 11) 0.21 (3.17%)
  • Put/Call Vol Ratio 0.03
  • Today's Volume 31
  • Volume Avg (30-Day) 90
  • Put/Call OI Ratio 1.33
  • Today's Open Interest 1,981
  • Open Int (30-Day) 3,871
  • Expected Range 6.49 to 6.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.24
  • Number of Estimates 3
  • High Estimate $-0.23
  • Low Estimate $-0.25
  • Prior Year $-0.36
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.84 +14.73%
on 04/13/26
7.23 -7.33%
on 04/20/26
+0.27 (+4.20%)
since 04/02/26
3-Month
4.80 +39.58%
on 03/09/26
7.99 -16.15%
on 02/27/26
-0.12 (-1.76%)
since 02/04/26
52-Week
3.76 +78.19%
on 09/10/25
8.95 -25.14%
on 01/13/26
+1.47 (+28.11%)
since 05/02/25

Most Recent Stories

More News
Profound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow

TORONTO, April 16, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...

PRN.TO : 9.12 (-2.88%)
PROF : 6.70 (-2.33%)
Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference

TORONTO, April 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...

PRN.TO : 9.12 (-2.88%)
PROF : 6.70 (-2.33%)
Incision-Free, MRI-Guided Prostate Treatment with Profound’s TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting

TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...

PRN.TO : 9.12 (-2.88%)
PROF : 6.70 (-2.33%)
Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone

TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...

PRN.TO : 9.12 (-2.88%)
PROF : 6.70 (-2.33%)
CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence

– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment – – TULSA...

PRN.TO : 9.12 (-2.88%)
PROF : 6.70 (-2.33%)
Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24

TORONTO, March 09, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...

PRN.TO : 9.12 (-2.88%)
PROF : 6.70 (-2.33%)
Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results

TORONTO, March 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...

PRN.TO : 9.12 (-2.88%)
PROF : 6.70 (-2.33%)
Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow

TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative...

PRN.TO : 9.12 (-2.88%)
PROF : 6.70 (-2.33%)
Profound Medical Honored with INOVAIT’s 2025–2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate Disease

TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage innovator in interventional MRI (“iMRI”) procedures,...

PRN.TO : 9.12 (-2.88%)
PROF : 6.70 (-2.33%)
PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women’s Health

TORONTO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...

PRN.TO : 9.12 (-2.88%)
PROF : 6.70 (-2.33%)

Business Summary

Profound Medical Corp. is a medical technology company. It is focused on a therapeutics platform which provides the precision of real-time Magnetic Resonance Imaging technology for the incision-free ablation of diseased tissue. The company principally commercialized the TULSA-PRO(R) and Sonalleve(R)...

See More

Key Turning Points

3rd Resistance Point 7.27
2nd Resistance Point 7.14
1st Resistance Point 6.92
Last Price 6.70
1st Support Level 6.57
2nd Support Level 6.44
3rd Support Level 6.22

See More

52-Week High 8.95
Fibonacci 61.8% 6.97
Last Price 6.70
Fibonacci 50% 6.36
Fibonacci 38.2% 5.74
52-Week Low 3.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.